Each individual can respond to the same doses of a drug in a different way, regarding to their own genetic variation patterns. Pharmacogenetics (PG) is the study or clinical testing of these genetic variations that gives rise to differing responses to drugs. PG also refers to genetic differences in metabolic pathways which can affect individual responses to drugs, both in terms of the therapeutic effect as well as adverse effects. Thus, PG studies are committed to select the best therapy for every patient with a minimum risk of complications. Furthermore, these studies allow the development of clinical tests based on the presence of profiles of biomolecules and other biological markers useful for routine diagnosis.
Since genetic variations play an important role in reproductive medicine, pharmacogenetics studies open a new field to modify and develop treatments for infertile couples. For instance, the application of PG to assisted reproductive techniques (ART) will help clinicians to improve the efficacy of hormone treatments that are being routinely applied during ART protocols. As an example, FSH- and estrogen-receptors are genetic markers involving controlled ovarian hyperstimulation as clinical studies have demonstrated that the p.N680S polymorphism of the FSH-receptor gene determines the less ovarian response to FSH stimulation in patients undergoing IVF. In women with homozygous Ser/Ser in their FSH-receptor, the FSH receptor appears to be more resistant to treatment. Therefore, genotyping of patients scheduled for ovarian stimulation could be an attractive tool to individualize FSH dosing according to genetic differences in ovarian sensitivity. Consequently, pharmacogenetics can assist physicians with prescribing medicine to achieve the controlled ovarian stimulation.
Our research outlines focus on genes that are involved in male/female infertility, particularly in ART-protocols response.
Parvaneh Afsharian, PhD
M Khosravi Far, MSc
Z Mansouri, MSc
A Mohseni Meybodi, PhD
Sh Zari Moradi, MSc